



IFW

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	10/801,122
Filing Date	March 15, 2004
First Named Inventor	Edward A. Neuwelt
Art Unit	
Examiner Name	
Attorney Docket No.	720109.405

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> 16 Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
--	---	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Qing Lin, Ph.D. Reg. No. 53,937	Customer Number 00500
Signature		
Date	June 8, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Lawrence Teague	
Signature		Date: June 8, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

488137



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

June 8, 2004 Lawrence Teague
Date Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Edward A. Neuwelt
Application No. : 10/801,122
Filed : March 15, 2004
For : USE OF THIOL-BASED COMPOSITIONS IN
AMELIORATING MUCOSAL INJURY

Docket No. : 720109.405
Date : June 8, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicant wishes to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicant does not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information he is aware of which is believed relevant to the examination of the above-identified application, applicant believes that his invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicant believes this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Qing Lin, Ph.D.

Registration No. 53,937

QXL:ljt

Enclosures:

Postcard

Transmittal Form

Form PTO-1449 (2 Sheets)

Cited References (16)

701 Fifth Avenue, Suite 6300

Seattle, Washington 98104-7092

Phone: (206) 622-4900

Fax: (206) 682-6031

V488135

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

720109.405

APPLICATION NO.

10/801,122

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Edward A. Neuwelt

FILING DATE

March 15, 2004

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AD	WO 01/80832	11/01/01	WIPO		
	AE					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AF	Barasch and Peterson, "Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions," <i>Oral Oncology</i> 39: 91-100, 2003.
	AG	Barreto, J.C. et al., "Protective action of oral N-acetylcysteine against gastric injury: role of hypertonic sodium," <i>American Journal of Physiology. Cell Physiology</i> 264(3): G422-G426, March 1993.
	AH	Brizel, D.M. et al., "Phase III Randomized Trail of Amifostine as a Radioprotector in Head and Neck Cancer," <i>Journal of Clinical Oncology</i> 18(19): 3339-3345, October 2000.
	AI	El-Sayed, S. et al., "Prophylaxis of Radiation-Associated Mucositis in Conventionally Treated Patients With Head and Neck Cancer: A Double-Blind, Phase III, Randomized, Controlled Trail Evaluating the Clinical Efficacy of an Antimicrobial Lozenge Using a Validated Mucositis Scoring System," <i>Journal of Clinical Oncology</i> 20(19): 3956-3963, October 2002.
	AJ	Filicko, J. et al., "Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment," <i>Bone Marrow Transplantation</i> 31: 1-10, 2003.
	AK	Fiorucci, S. et al., "TNF α processing enzyme inhibitors prevent aspirin-induced TNF α release and protect against gastric mucosal injury in rats," <i>Aliment Pharmacol. Ther.</i> 12(11): 1139-1153, November 1998.
	AL	Kohno, N. et al., "Survival Results of Neoadjuvant Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck," <i>Jpn. J. Clin. Oncol.</i> 30(6): 253-258, 2000.
	AM	Koukourakis, M., "Amifostine in clinical oncology: current use and future applications," <i>Anti-Cancer Drugs</i> 13: 181-209, 2002.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

720109.405

APPLICATION NO.

10/801,122

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Edward A. Neuwelt

FILING DATE

March 15, 2004

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BD					
	BE					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BF	Lopez, R.A. et al., "N-Acetyl-Cysteine: Protective Agent of Promoter of Gastric Damage?" <i>Proceedings of the Society for Experimental Biology and Medicine</i> 197: 273-278, 1991.
	BG	Okajima, K. et al., "Inhibition of neutrophil activation by ranitidine contributes to prevent stress-induced gastric mucosal injury in rats," <i>Critical Care Medicine</i> 28(8): 2858-2865, August 2000.
	BH	Renner, S. et al., "Effect of Amifostine on Neuroblastoma during High Dose Chemotherapy: <i>In Vivo</i> and <i>In Vitro</i> Investigations," <i>Anticancer Research</i> 20: 4531-4538, 2000.
	BI	Salim, A.S., "Scavenging Free Radicals to Prevent Stress-Induced Gastric Mucosal Injury," <i>The Lancet</i> 2(8676): 1390, December 9, 1989.
	BJ	Santini and Giles, "The potential of amifostine: from cytoprotectant to therapeutic agent," <i>Haematologica</i> 84(11): 1035-1042, November 1999.
	BK	Seril, D.N. et al., "Inhibition of chronic ulcerative colitis-associated colorectal adenocarcinoma development in a murine model by N-acetylcysteine," <i>Carcinogenesis</i> 23(6): 993-1001, 2002.
	BL	Van Schooten, F.J. et al., "Effects of Oral Administration of N-Acetyl-L-cysteine: A Multi-Biomarker Study in Smokers," <i>Cancer Epidemiology, Biomarkers & Prevention</i> 11: 167-175, February 2002.
	BM	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).